权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) Study

抗血小板干预 2 (PAPI-2) 研究的药物基因组学

基本信息

批准号：
8536354
负责人：
ALAN R. SHULDINER
金额：
$ 227.41万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-23 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8536354
关键词：
Accounting Address Affect African American Aftercare Age Algorithms Alleles Amish Architecture Aspirin Biology Blood Platelets Blood group antibody D CCL18 gene CYP2C19 gene Cardiac Cardiovascular system Cessation of life Clinical Clinical Trials Collaborations Coronary heart disease DNA DNA Resequencing Data Databases Deposition Dose Double-Blind Method Educational workshop Ethnic Origin Event Exons Family member Founder Generation Funding General Population Genes Genetic Genetic Variation Genomics Genotype Goals Health Health Care Costs Hemorrhage Hospitals Hour Individual Intervention Measures Medicine Morbidity - disease rate Mutation Myocardial Infarction Patients Pharmaceutical Economics Pharmacogenomics Phenotype Platelet aggregation Plavix Population Principal Investigator Procedures Randomized Randomized Clinical Trials Recruitment Activity Research Research Personnel Rest Sampling Science Secondary Prevention Secure Signal Transduction Single Nucleotide Polymorphism Solutions Staging Tail Testing Translations Validation Variant Work arm caucasian American clinical practice clinical research site clopidogrel cohort cost effective design evidence base exome sequencing follow-up genetic variant genome wide association study genome-wide high risk human CYP2C19 protein improved insight loss of function member mortality multidisciplinary novel prevent primary outcome prospective response secondary outcome sex standard of care symposium trait trial comparing

项目摘要

DESCRIPTION (provided by applicant): Anti-platelet therapy with clopidogrel (Plavix) and aspirin is the standard of care for secondary prevention of myocardial Infarction. Despite its widespread use, 4 - 32% of Individuals are not responsive to clopidogrel. This renewal application will build upon significant progress made during the initial funding period in which we completed the Amish Pharmacogenomics of Anti-platelet lnterventlon-1 (PAPI-1) Study. Through the first genome-wide association study (GWAS) of its kind, we found that the loss of function cytochrome P450 2C19*2 (CYP2C19*2) variant is a major determinant of clopidogrel response, accounting for 12% of the variation in response. In an Independent cohort, we found that ~30% of the general population harboring CYP2C19*2 have poorer platelet response to clopidogrel and are at a 2.4-fold higher risk of having an ischemic cardiac event or death. The overall goal of this renewal application is to continue to advance the science of anti-platelet pharmacogenomics and its clinical translation. We hypothesize (a) CYP2C19 genotype-directed anti-platelet therapy will be superior to standard of care therapy; and (b) the genetic architecture of clopidogrel response Includes common and rare variants in yet-to-be identified genes. We have amassed a team of multidisciplinary investigators and collaborators and will capitalize on synergies created by active participation in the Pharmacogenomics Research Network to address the following Specific Alms: (1) To conduct the PAPI-2 Study, a prospective multicenter randomized double-blind clinical trial comparing cardiovascular events using CYP2C19 genotype-directed versus standard of care anti-platelet therapy in over 2000 patients with coronary heart disease; (2) To identify common variants in novel genes and loci for clopidogrel response by performing a large GWAS as part of a new Clopidogrel Pharmacogenomics GWAS Consortium; and (3) To identify rare variants in genes previously not known to influence platelet function or clopidogrel response by performing genome-wide exon (exome) sequencing from the extremes of the distribution of clopidogrel response. RELEVANCE: The proposed randomized clinical trial will provide the evidence base for translation of genotype-directed anti-platelet therapy into clinical practice. The Identification of common and rare variants in novel genes for clopidogrel response will provide new insights into platelet biology and variation in anti-platelet therapy response, and potentially, new targets for more effective agents to prevent and treat CHD.

描述（由申请方提供）：氯吡格雷（Plavidine）和阿司匹林抗血小板治疗是心肌梗死二级预防的标准治疗。尽管氯吡格雷被广泛使用，但仍有4 - 32%的个体对氯吡格雷无反应。该更新申请将建立在我们完成Amish抗血小板药物基因组学干预-1（PAPI-1）研究的初始资助期间取得的重大进展的基础上。通过首次全基因组关联研究（GWAS），我们发现细胞色素P450 2C 19 *2（CYP 2C 19 *2）变异体功能丧失是氯吡格雷反应的主要决定因素，占反应变异的12%。在一项独立队列研究中，我们发现约30%携带CYP 2C 19 *2的一般人群对氯吡格雷的血小板反应较差，发生缺血性心脏事件或死亡的风险高2.4倍。本次更新申请的总体目标是继续推进抗血小板药物基因组学及其临床转化的科学。我们假设：（a）CYP 2C 19基因型导向抗血小板治疗上级标准治疗;（B）氯吡格雷反应的遗传结构包括尚待鉴定的基因中的常见和罕见变异。我们已经积累了一个多学科研究者和合作者团队，并将利用积极参与药物基因组学研究网络所产生的协同效应，以解决以下具体问题：（1）进行PAPI-2研究，一项前瞻性多中心随机双盲临床试验，比较使用CYP 2C 19基因型导向与标准治疗抗-在2000多名冠心病患者中进行血小板治疗;（2）通过进行大型GWAS（作为新的氯吡格雷药物基因组学GWAS联盟的一部分），鉴定氯吡格雷应答的新基因和位点的常见变异;和（3）通过进行全基因组外显子（外显子组）检测，鉴定以前不知道会影响血小板功能或氯吡格雷反应的基因中的罕见变异。从氯吡格雷反应分布的极值开始排序。相关性：拟开展的随机临床试验将为基因型导向抗血小板治疗转化为临床实践提供证据基础。氯吡格雷反应新基因中常见和罕见变异的鉴定将为血小板生物学和抗血小板治疗反应的变异提供新的见解，并可能为更有效的药物预防和治疗CHD提供新的靶点。